Seegene launches a new anti-microbial drug resistance test kit, replacing the conventional culture method

SEOUL, Korea, Nov 26, 2018 ? Seegene Inc. (096530.KQ), a leading developer of multiplex PCR assays, announced that multi-site clinical trials for measuring clinical performance on screening the dru...

Seegene Unveils New Real-time PCR Analysis Technology, Drastically Increasing Its Multiplexing Capacity

SEOUL, Korea, Sept 19, 2018 ? Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced its proprietary technology, “MuCT™”. This is a real-time PCR based data ac...

Seegene Unveils Combination Test at ECCMID 2018

Seoul, Korea, 2018/04/17 - Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, announced that it will attend the 28th European Congress of Clinical Microbiology and Infecti...

Seegene develops world’s first multiplex MDx assays with its AI system

Seoul, South Korea - Jan 3, 2018 - Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced today that, utilizing a newly created artifici...

Seegene inks MOU with global automated instrumentation leader Hamilton Company

Seoul, Korea, 2017/09/26 - Seegene, a world's leading developer of multiplex molecular technologies and assays, announced that it has signed a Memorandum of Understanding (MOU) with Hamilton Compan...

Seegene accelerates ‘Project 100’ by securing 30 co-development partners

Seoul, Korea, 2017/08/31 - Seegene, the world’s leading developer of multiplex molecular technologies and assays, announced that it has recently signed collaborative contracts with 30 general...

Unique concept of MDx, Seegene Random Access System, announced at AACC 2017

Seoul, South Korea - July 26, 2017 - Seegene Inc. (096530.KQ), the world’s leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Rando...

Seegene Signed MOU with a Mexico Government Agriculture Agency for Collaborative Development of Non-human MDx Assay

SEOUL, South Korea, June 21, 2017-- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, today announced an MOU entering into partnership with o...

Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific

Seoul, Korea, 2017/05/23 - Seegene Inc. (096530.KQ), the world’s leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new s...

Seegene Unlocks the Door to the Next Level of the Real-time PCR Business

SEOUL, South Korea, April 26, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the leading developer of multiplex PCR technologies, announced that it is entering into more innovative and powerful bus...

Seegene Develops New Normalization Software Technology for Molecular Diagnosis

Seegene Develops New Normalization Software Technology for Molecular Diagnosis SEOUL, South Korea, Feb. 14, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PC...

[INTERVIEW] Seegene will hit molecular diagnostic milestone in 2017: CEO

Seegene and Institut Catala d

Seegene and Institut Catala d'Oncologia(ICO) enter MOU for mutual cooperation   - Conducting clinical research with clinical specimens related to cancers and developing cancer diagnost...

Seegene y el ICO colaboraran en estudios de diagnostico del cancer